LFSC
F/m Emerald Life Sciences Innovation ETF
Price Chart
Latest Quote
$45.70
+0.93 (+2.08%)
Current Price
| Previous Close | $44.77 |
| Open | $45.80 |
| Day High | $46.02 |
| Day Low | $45.62 |
| Volume | 6,614 |
Fund Information
| Net Assets | $121.85M |
| Expense Ratio | 0.54% |
| Category | Health |
| Fund Family | Emerald Mutual Fund Advisers Trust |
| Net Asset Value | $44.94 |
| Premium/Discount | 1.69% |
| Exchange | NGM |
📊 ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $45.11 |
| SMA50 | $41.24 |
| SMA200 | $36.71 |
| RSI | 54.08 |
| ATR | 0.9685 |
| Rel Volume | 0.99 |
Performance History
| Week | -1.27% |
| Month | +13.05% |
| Quarter | +21.93% |
| 6 Months | +26.44% |
| YTD | +26.17% |
| Year | +81.35% |
| 10 Years | +83.61% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $45.70 | 6,614 |
| 2026-07-16 | $44.90 | 5,300 |
| 2026-07-15 | $46.21 | 1,700 |
| 2026-07-14 | $45.63 | 1,800 |
| 2026-07-13 | $45.19 | 27,000 |
| 2026-07-10 | $46.29 | 5,000 |
| 2026-07-09 | $47.38 | 18,800 |
| 2026-07-08 | $46.56 | 3,400 |
| 2026-07-07 | $46.91 | 14,500 |
| 2026-07-06 | $46.38 | 7,300 |
| 2026-07-02 | $46.14 | 11,100 |
| 2026-07-01 | $45.44 | 700 |
| 2026-06-30 | $45.20 | 6,400 |
| 2026-06-29 | $45.47 | 6,300 |
| 2026-06-26 | $44.97 | 5,800 |
| 2026-06-25 | $44.13 | 1,600 |
| 2026-06-24 | $43.29 | 1,300 |
| 2026-06-23 | $42.60 | 900 |
| 2026-06-22 | $42.38 | 2,200 |
| 2026-06-18 | $41.52 | 5,600 |
About F/m Emerald Life Sciences Innovation ETF
The fund is an actively managed exchange-traded fund (“ETF”) and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust, the fund’s investment sub-adviser, under the supervision of the adviser. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities issued by life science companies demonstrating innovation.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.